Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

37.87 -1.33 (-3.39%)
Streaming Delayed Price Updated: 2:12 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO International Convention
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at EULAR 2025 in Barcelona
Via Investor Brand Network
Exposures Product Safety
What's Going On With Tonix Pharmaceuticals Stock?
Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) shares have nearly doubled over the past month. Here's what you need to know. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins A.G.P. Healthcare Showcase Fireside Chat
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Doses First Patient in DoD-Backed OASIS Trial for Acute Stress Reaction
Via Investor Brand Network
Exposures Product Safety
The market is filled with gapping stocks in Friday's session.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results
Tonix stock surged over 33% this week fueled by insider buying and strong Q1 results. The company's Q1 loss beat estimates. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive
In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration. 
Via Stocktwits
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Joseph Hand as General Counsel and EVP of Operations
Via Investor Brand Network
Exposures Product Safety
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Prepares for Potential Fibromyalgia Drug Approval, Reports Q1 Results
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data for TNX-1700 at AACR 2025
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Showcases Single-Dose Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Collaborates With Makana Therapeutics on Xenotransplantation Research
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Data on Fibromyalgia Drug at AAPM 2025
Via Investor Brand Network
Exposures Product Safety
Peering Into Tonix Pharmaceuticals's Recent Short Interest
Via Benzinga
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at 2025 Jones Trading Healthcare Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches TONIX ONE™ Digital Platform to Transform Migraine Care
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Drug Toward FDA Decision
Via Investor Brand Network
Exposures Product Safety
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
Via ACCESS Newswire
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.
Via ACCESS Newswire
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL. 
Via Benzinga
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at AAPM 2025 PainConnect Meeting
Via Investor Brand Network
Exposures Product Safety
Pharma Frenzy: Volatility Ignites Biotech Sector
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value. 
Via MarketBeat
Exposures Product Safety
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Traders are paying attention to the gapping stocks in Monday's session.
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Discover the top movers in Monday's pre-market session.
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review
Via Investor Brand Network
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.